PepBank has 1 follistatin-344 study with results. It gave follistatin-344, with 4 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 4 results and 3 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Follistatin-344 denotes the 344-residue precursor of a secreted follistatin isoform. UniProt annotates removal of a 29-residue signal peptide, which produces a 315-residue mature chain. Follistatin binds activins. Retail use of the name does not establish the identity, processing or purity of the supplied protein. Gene transfer studies do not test injection of retail FST344.
| Target | Action | Evidence |
|---|---|---|
| Activin AINHBAP08476 (opens in a new tab) | Antagonist | knownSource (opens in a new tab) |
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
344 amino acids · 2 modifications · 18 disulfide bonds
No formula or molecular weight is listed for Follistatin-344.
Some values cannot be calculated. A modification changes this value and is not modeled here (for example a lipid, metal or linker).
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
No charge curve
A modification changes this value and is not modeled here (for example a lipid, metal or linker).
344 residues. Each residue counts in one class; F and W count as aromatic.
Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).
An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.
Eisenberg consensus (normalized) scale · + K, R · − D, E
Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.
| Position | Residue | Angle | Eisenberg consensus (normalized) |
|---|---|---|---|
| 1 | M | 0° | 0.64 |
| 2 | V | 100° | 1.08 |
| 3 | R | 200° | -2.53 |
| 4 | A | 300° | 0.62 |
| 5 | R | 40° | -2.53 |
| 6 | H | 140° | -0.40 |
| 7 | Q | 240° | -0.85 |
| 8 | P | 340° | 0.12 |
| 9 | G | 80° | 0.48 |
| 10 | G | 180° | 0.48 |
| 11 | L | 280° | 1.06 |
| 12 | C | 20° | 0.29 |
| 13 | L | 120° | 1.06 |
| 14 | L | 220° | 1.06 |
| 15 | L | 320° | 1.06 |
| 16 | L | 60° | 1.06 |
| 17 | L | 160° | 1.06 |
| 18 | L | 260° | 1.06 |
| 19 | C | 0° | 0.29 |
| 20 | Q | 100° | -0.85 |
| 21 | F | 200° | 1.19 |
| 22 | M | 300° | 0.64 |
| 23 | E | 40° | -0.74 |
| 24 | D | 140° | -0.90 |
| 25 | R | 240° | -2.53 |
| 26 | S | 340° | -0.18 |
| 27 | A | 80° | 0.62 |
| 28 | Q | 180° | -0.85 |
| 29 | A | 280° | 0.62 |
| 30 | G | 20° | 0.48 |
| 31 | N | 120° | -0.78 |
| 32 | C | 220° | 0.29 |
| 33 | W | 320° | 0.81 |
| 34 | L | 60° | 1.06 |
| 35 | R | 160° | -2.53 |
| 36 | Q | 260° | -0.85 |
| 37 | A | 0° | 0.62 |
| 38 | K | 100° | -1.50 |
| 39 | N | 200° | -0.78 |
| 40 | G | 300° | 0.48 |
| 41 | R | 40° | -2.53 |
| 42 | C | 140° | 0.29 |
| 43 | Q | 240° | -0.85 |
| 44 | V | 340° | 1.08 |
| 45 | L | 80° | 1.06 |
| 46 | Y | 180° | 0.26 |
| 47 | K | 280° | -1.50 |
| 48 | T | 20° | -0.05 |
| 49 | E | 120° | -0.74 |
| 50 | L | 220° | 1.06 |
| 51 | S | 320° | -0.18 |
| 52 | K | 60° | -1.50 |
| 53 | E | 160° | -0.74 |
| 54 | E | 260° | -0.74 |
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Studies by year
1 of 3 studies has results (33%), published 2020. Top row: every study. Bottom row: studies with results about Follistatin-344, by class. The rows use different scales.
Studies3 in all, 2019 to 2020
Studies with results1 in all, 2020
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
0 trials match. Highest phase first. Data from ClinicalTrials.gov.
No trial matches these filters.
1 more mentions it but does not test it. They are not trials of Follistatin-344: they only measure it (a blood level or an eligibility term) or name it in their text.
Studies on this peptide. Some have results. The others have none yet.
3 studies match. Retracted studies are left out.
Showing 3 of 3 studiesquery qry_b4809b0a1e47182791558024
1 study
Case report or series · 2020
Dağ et al. 2020International ophthalmologyn = 11cited by 2
PMID 32671599DOI 10.1007/s10792-020-01501-6PUB-32671599
2 studies
PubMed tag: none · 2019
Reichel et al. 2019Drug testing and analysiscited by 8
PMID 31758732DOI 10.1002/dta.2741PUB-31758732
PubMed tag: none · 2020
Reichel et al. 2020Drug testing and analysis
PMID 33460286DOI 10.1002/dta.2882PUB-33460286
Page 1 of 1
Dağ U · International ophthalmology · 2020
Case report or series · 4 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA | The openFDA Drugs@FDA active ingredient searches returned no matches for follistatin, FST344 or FS344. The Purple Book search returned an access denial. Complete FDA approval exclusion remains unresolved. The nomination lists do not establish approval status. | 13 Oct 2026 | api.fda.gov (opens in a new tab) |
| EU | EMA | No matching active substance in the EMA central medicines data file. National authorisations are not covered. | 13 Oct 2026 | ema.europa.eu (opens in a new tab) |
| Sport | WADA | Banned in sport (WADA S4.3) The 2026 list names follistatin as a myostatin-binding protein under S4.3, agents preventing activin receptor IIB activation. | 2026 List | wada-ama.org (opens in a new tab) |
| Russia | Note | National medicine registration not established in this profile. | 13 Oct 2026 | Not recorded |
4 safety results for Follistatin-344.
In bodybuilding athletes, CSCR followed high-dose follistatin‑344 injections in 11 patients, with unilateral disease in ten and bilateral disease in one.
Case report or seriesn = 11
In eight patients with one previous follistatin‑344 injection, subretinal fluid disappeared after an average of 2.3 ± 0.7 months.
Case report or seriesn = 8
In eight patients with one previous follistatin‑344 injection, CSCR symptoms regressed.
Case report or seriesn = 8
In three patients with multiple previous follistatin‑344 injections, recurrent CSCR developed.
Case report or seriesn = 3
The doses that these studies used. They are not recommendations.
1 mgHuman
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https://Evidence summary for Follistatin-344: counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
The 1 outcome groups with the most study results, by evidence class.
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
| Outcome group | Human | Animal | Lab | Computer model | Total |
|---|---|---|---|---|---|
| Adverse eventsEye | Human: 4 results from 1 study: 2 decrease, 2 not reported. Strongest design: Case report or series | No results | No results | No results | 4 |
1 outcome group shown of 1 · 4 study results
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.